Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2016 08:30 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
March 07, 2016 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., Announces Ticker Symbol Change to “OPNT”

SANTA MONICA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for...
March 07, 2016 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma Limited’s First Commercial Sale of NARCAN® (Naloxone Hydrochloride) Nasal Spray in the U.S.

SANTA MONICA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for...
February 17, 2016 08:45 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., Convenes Medical Advisory Board to Support Development of Pharmacological Treatments for Substance Use, Addictive and Eating Disorders

SANTA MONICA, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
February 17, 2016 08:30 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc. Announces Name Change to Opiant Pharmaceuticals, Inc.

SANTA MONICA, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
February 16, 2016 09:00 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc. Expands Drug Development Capabilities by Appointing Mark Ellison, Ph.D., as Executive Vice President Development, Manufacturing and Quality

NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
January 27, 2016 09:00 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan® (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education

NEW YORK, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
January 19, 2016 09:00 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN® (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities

NEW YORK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
December 23, 2015 09:00 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania

NEW YORK, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
December 15, 2015 09:00 ET | Source: Opiant Pharmaceuticals, Inc.

Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray

NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...